Experimental combo aims to outsmart tough leukemia

NCT ID NCT05627232

Recruiting now Disease control Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests two different drug combinations for people whose acute myeloid leukemia (AML) has returned or not responded to prior treatment. In Part 1, participants receive tazemetostat plus a standard chemotherapy called CPX-351. In Part 2, they get palbociclib before CPX-351. The study enrolls 24 adults and focuses on finding safe doses and watching for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tazemetostat and CPX-351 (liposomal daunorubicin-cytarabine) in Part 1; palbociclib followed by CPX-351 in Part 2
What this could lead to: If successful, this could point toward a new combination treatment for acute myeloid leukemia that has come back or not responded to standard therapy.
What could go wrong: This is a very early (Phase 1) trial with only 24 participants, so the main goal is safety, not proof of effectiveness. The combinations may cause serious side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT ACUTE MYELOID LEUKEMIA REFRACTORY ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Thomas Jefferson University Hospital
RECRUITING

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.